What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short version

• Since 2023 the FDA has cracked down on compounding pharmacies that make “copycat” GLP‑1 products (semaglutide, tirzepatide and similar peptides). The agency’s position: pharmacies may not lawfully compound essentially the same product as an FDA‑approved drug or an unlicensed biologic, and many compounded GLP‑1 preparations raise safety and quality concerns. That led to warning letters, seizures and many compounders stopping production.
• That doesn’t mean every pharmacy is shut down. Legally operating options now are (a) FDA‑approved GLP‑1 drugs made by the manufacturers and dispensed by regular pharmacies, and (b) compounding pharmacies that follow the narrow legal pathways (patient‑specific compounding under state law or registered 503B outsourcing facilities that comply with FDA rules).

What the FDA action was and why

• FDA message: compounding cannot be used to recreate commercially available, FDA‑approved drugs (or unapproved biologics) to get around approval and safety requirements. Compounded GLP‑1s were often made from bulk peptide APIs and sold widely without the testing/controls required for approved products — prompting FDA warnings and enforcement.
• Enforcement steps have included warning letters to specific compounders, seizures, and public notices telling prescribers and patients to be cautious about compounded GLP‑1s.

Who is still operating legally

1. FDA‑approved manufacturers/distributors (the safest/legal route)

   • Novo Nordisk — Ozempic and Wegovy (semaglutide). Widely available by prescription through mainstream pharmacies and clinics.
   • Eli Lilly — Mounjaro and Zepbound (tirzepatide). Available by prescription.
   • (Also: Rybelsus, other approved GLP‑1 products depending on indication.) Why use them: these products went through FDA review for safety, manufacture under GMP, and have supply/distribution through licensed pharmacies.

2. Licensed 503A compounding pharmacies (state‑law, patient‑specific)

   • These can legally compound medications for an individual patient based on a valid prescription, but may not legally make widespread “copies” of approved GLP‑1 drugs. Whether a particular 503A pharmacy can lawfully compound a GLP‑1 depends on state rules and whether the product would be considered an essentially identical copy of an approved drug.
   • If you’re prescribed a compounded GLP‑1, ask the pharmacy how they comply with state law, and for sterility/quality testing results.

3. FDA‑registered 503B outsourcing facilities

   • 503B facilities register with FDA and can produce compounded drugs in bulk for hospitals/clinics, but they are explicitly prohibited from compounding a drug that is essentially a copy of an FDA‑approved drug or an unlicensed biologic. Some 503B facilities remain active but must follow FDA limits.
   • You can check the FDA’s current list of registered outsourcing facilities to confirm registration.

4. State‑licensed clinics and prescribers

   • Some medical practices still prescribe FDA‑approved GLP‑1s and may use in‑office dispensing or pharmacies that meet legal requirements. Avoid clinics offering mail‑order “compounded semaglutide” without clear documentation of legality and testing.

How to tell a pharmacy or service is operating legally and safely

• Prefer FDA‑approved products from major manufacturers (Novo Nordisk, Eli Lilly) filled at mainstream pharmacies (CVS, Walgreens, Walmart or your independent local pharmacy).
• If considering a compounded product, ask the pharmacy to provide:
  • Whether they are a 503A (state) or 503B (FDA) facility and proof of registration/licensure.
  • Certificate of Analysis (CoA) for the active ingredient and sterility testing for injectable products.
  • Evidence of sterile compounding accreditation (PCAB or other credible accreditation).
• Don’t buy GLP‑1 injections from online vendors that don’t require a prescription, that ship internationally, or that won’t provide batch testing.

Practical recommendation

• For safety and legality, get GLP‑1 therapy through a licensed prescriber and ask to use FDA‑approved products (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus) dispensed by a reputable pharmacy. If a compounded product is proposed, insist on written documentation as described above and verify the compounding pharmacy’s 503A/503B status and testing.

If you want, I can:

• Walk you through questions to ask a compounding pharmacy,
• Check current FDA resources for registered 503B facilities, or
• Help find local clinics or pharmacies that dispense FDA‑approved GLP‑1s.